Analysts Issue Forecasts for Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of Pyxis Oncology in a note issued to investors on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the company will earn ($0.32) per share for the quarter. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Other equities analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price objective on shares of Pyxis Oncology in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.20.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.21 on Friday. The stock has a market cap of $74.52 million, a P/E ratio of -1.17 and a beta of 1.11. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The stock has a 50 day simple moving average of $1.33 and a two-hundred day simple moving average of $2.35.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The firm had revenue of $16.15 million for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. MetLife Investment Management LLC boosted its position in shares of Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares in the last quarter. Bank of America Corp DE lifted its position in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after buying an additional 9,062 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Pyxis Oncology by 61.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after buying an additional 10,000 shares in the last quarter. Barclays PLC boosted its holdings in shares of Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock valued at $121,000 after buying an additional 12,924 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after buying an additional 14,349 shares during the period. Hedge funds and other institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.